ArticleFrontiers in immunology2025
Transcriptional responses in different mouse models of septic liver injury differ from those in patients with septic liver injury.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimization of a fresh fecal intraperitoneal injection sepsis model and its divergent dynamics from cecal ligation and puncture in mice.Laboratory animal research · 2026Article
- Maresin-1 Alleviates Sepsis-Induced Liver Injury by Regulating Apoptosis and Autophagy via Activation of the PI3K/Akt Signaling Pathway in Mice.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sepsis, particularly sepsis-induced liver injury (SLI), exhibits acute onset and high mortality (up to 80%). While murine models are widely used for mechanistic studies due to limited human sample availability, their accuracy in replicating human SLI pathophysiology remains debated. Methods: Human SLI transcriptomes were characterized to identify core genes and immune signatures using Venn analysis and immune infiltration profiling. Transcriptomic features of two murine SLI models-cecal ligation and puncture (CLP) and lipopolysaccharide (LPS) challenge-were benchmarked against human SLI to evaluate pathophysiological relevance. Both models were then utilized to validate core gene expression for SLI biomarker identification. Results: Human SLI transcriptomics revealed significant enrichment in apoptotic processes, NF-κB regulation, inflammatory responses, protein phosphorylation, and bacterial response. Key pathways included IL-17 signaling, antigen processing, estrogen signaling, and atherosclerosis. Immune infiltration confirmed multifactorial immune cell involvement. Both murine models recapitulated inflammatory and immune responses, with the LPS model mimicking human SLI via chemotaxis, phagocytosis, NOD-like receptor signaling, and leukocyte migration. The CLP model uniquely replicated neutrophil chemotaxis, apoptosis, ER stress, IL-17, and TNF signaling. SOCS3 was validated as a potential SLI biomarker. Discussion: Murine models partially replicate human SLI pathology but exhibit distinct mechanistic emphases. Careful model selection is essential for biomarker discovery (e.g., SOCS3) and pathogenic mechanism exploration, highlighting inherent model limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.